Pranela Rameshwar, Ph.D.
Department of Medicine
Rutgers – New Jersey Medical School
Title: Mesenchymal stem cells (MSCs)
Mesenchymal stem cells (MSCs) are in clinical trials for a variety of disorders. To date, there is no report of deleterious effect noted for MSCs. Early studies suggested that MSCs were mesodermal in origin. However, more recent studies seem to indicate that MSCs could be neuroectodermal in origin. The advantages of MSCs in translational applications are mainly due to their availability as `off the shelf’ stem cells, reduced ethical concerns, ease in expansion and plasticity. Indications for MSCs include, but are not limited to inflammatory diseases, tissue repair and protection, neuronal disorder and, cellular vehicle for drugs and RNA. Despite the promise of MSCs for tissue regeneration, there are concerns on the safety since MSCs can also support and protect tumors. This seminar will use a model of breast cancer stem cells (CSCs) to discuss the interaction with MSCs. Data will be presented to show how MSC-released exosomes mediate intercellular communication with CSCs. The consequence for stem cell therapy will be discussed.
View the presentation (PDF)